Apimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab™ Program collaboration with the University of Oregon’s Lundquist College of Business

MATAWAN, N.J. & EUGENE, Ore.--(BUSINESS WIRE)-- Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) (“Apimeds”) today announced the expansion of the Apimeds ai^² Futures Lab program through a new collaboration with the University of Oregon’s Lundquist College of Business, starting with the Winter 2026 quarter. The initiative connects student teams with real-world biopharma business development projects, reinforcing Apimeds’ commitment to fostering innovation, leadership, and discovery across the healthcare ecosystem.

ai^² Futures Lab functions as both a discovery engine for potential therapeutic assets and a training ground for tomorrow’s industry leaders. Through this collaboration, University of Oregon students will engage directly with Apimeds mentors to evaluate early-stage or shelved pharmaceutical assets, conduct market and IP analysis, and identify opportunities to advance patient care through novel business strategies.

“As a proud University of Oregon alum, I couldn’t be more excited,” said Erik Emerson, CEO of Apimeds Pharmaceuticals. “The Lundquist College of Business is an ideal partner to help expand our ai^² Futures Lab initiative. This program embodies what we value most at Apimeds—bridging human insight and scientific innovation. ai^² Futures Lab fuels our pipeline with fresh, data-driven thinking, while allowing students at the University of Oregon to build on the Oregon tradition of innovation, collaboration and, as Oregon alumni appreciate, being your favorite team’s favorite team.”

Bruce Blonigen, Edward Maletis Dean of the Lundquist College of Business, added, “We’re thrilled to bring this hands-on opportunity to our students. Collaborating with an innovative partner like Apimeds provides real-world experience that helps prepare students for careers at the intersection of science, business, and innovation. It’s a perfect reflection of the Lundquist approach—learning by doing, with purpose and impact.”

Brian Peters, SVP of Apimeds’ ai^² Division and ai^² Futures Lab program lead, noted, “This partnership deepens our mission to transform ai^² Futures Lab into a scalable development platform for Apimeds and a launchpad for young innovators. Each team is working on real assets with real potential, creating value both for the company and for the students shaping the future of healthcare.”

The University of Oregon is the third academic institution with which the ai^² Futures Lab is collaborating, following the University of Alabama and the University of San Diego. The program continues to expand as a cornerstone of Apimeds’ ai^² innovation platform, which integrates actual intelligence—the power of human insight—with AI-driven analytics to identify transformative opportunities in biotechnology.

About Apimeds Pharmaceuticals

Apimeds Pharmaceuticals (NYSE American: APUS) is a clinical-stage biopharmaceutical company focused on developing non-opioid, biologic-based therapies for pain management. The company’s lead product candidate, Apitox, is in late-stage clinical development for osteoarthritis of the knee. For more information visit www.apimedsus.com. Information on the Apimeds’ website does not constitute a part of and is not incorporated by reference into this press release.

About the University of Oregon Lundquist College of Business

The University of Oregon’s Lundquist College of Business delivers a dynamic learning environment that boasts top-ranked programs in sports business, entrepreneurship, sustainable business, marketing, finance, operations, and accounting. With a strong emphasis on experiential learning and industry engagement, Lundquist prepares students to lead and innovate in a rapidly evolving global business landscape.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Apimeds undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Apimeds will be realized or, even if substantially realized, that they will have the expected consequences to or effects on the company or its business or operations. Readers are cautioned that certain important factors may affect Apimeds’ actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect Apimeds’ results include, but are not limited to, the ability of Apimeds to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to Apimeds’ ability to advance its product candidate and successfully complete clinical trials; risks relating to its ability to hire and retain qualified personnel; and the additional risk factors described in Apimeds’ filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on April 15, 2025 (as amended on May 2, 2025)

View source version on businesswire.com: https://www.businesswire.com/news/home/20251013682339/en/

Media Contact

Brian Peters

919.602.6557

Source: Apimeds Pharmaceuticals US, Inc.